Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

The Lancet
Sep 11, 2021 Volume 398 Number 10304 p931-1020, e14
https://www.thelancet.com/journals/lancet/issue/current

 

Articles
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Amy Flaxman, et al. and the Oxford COVID Vaccine Trial group
Open Access